Live Earnings Conference Call: Atea Pharmaceuticals will host a live Q2 2026 earnings call on August 12, 2026 at 4:30PM ET. NASDAQ:AVIR Atea Pharmaceuticals Q2 2026 Earnings Report $5.10 +0.05 (+0.99%) As of 01:56 PM Eastern ProfileEarnings HistoryForecast Live Call not available Upcoming EventEarnings Conference CallAtea Pharmaceuticals Q2 202600:00 / 00:00Live Transcript Follow Audio Atea Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.56Beat/MissN/AOne Year Ago EPSN/AAtea Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$33.03 millionBeat/MissN/AYoY Revenue GrowthN/AAtea Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateWednesday, August 12, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Atea Pharmaceuticals Earnings HeadlinesAtea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026August 5, 2026 | globenewswire.comAtea’s Renal and Hepatic Impairment Study Marks a Key De-Risking Step for AVIR InvestorsJuly 31, 2026 | tipranks.comOne Ticker Tied to a Major White House Move You Should KnowLarry Benedict made 274 million dollars for his clients by spotting major market moves before they happened. Now he is naming one ticker tied to a major White House policy shift that could stand out from the crowd.August 12 at 1:00 AM | Brownstone Research (Ad)Atea Pharmaceuticals says hepatitis C drug matches Gilead's in pivotal trialJuly 28, 2026 | msn.comAtea drops despite late-stage trial win for hepatitis C therapyJuly 28, 2026 | seekingalpha.comAtea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C VirusJuly 28, 2026 | globenewswire.comSee More Atea Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atea Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atea Pharmaceuticals and other key companies, straight to your email. Email Address About Atea PharmaceuticalsAtea Pharmaceuticals (NASDAQ:AVIR) is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia. Through strategic collaborations with pharmaceutical partners and research institutes, the company enhances its R&D capabilities, optimizes clinical development pathways and positions its therapies for potential global commercialization. Atea’s leadership team brings extensive experience in antiviral drug discovery, clinical development and regulatory strategy. Under their guidance, the company has advanced multiple development candidates from preclinical stages into human trials. Atea continues to expand its scientific platform through in-licensing opportunities and collaborative research, with a goal of delivering safe and effective antiviral treatments to improve patient outcomes and respond to evolving public health challenges.View Atea Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CoreWeave's $129 Billion AI Backlog Changes the Bull CaseFastly’s Q2 Rally Shows Investors Are Buying the Edge AI TurnaroundA Westinghouse IPO Could Reset the Nuclear Stock ConversationVisa’s AI Opportunity Is Hiding in Every TransactionOn Holding's Price Stumble May Be an Opening for a Company Built to RunRocket Lab’s Record Quarter Still Left Investors Waiting on NeutronAtlassian Just Pulled Off the Software Comeback Wall Street Wanted Upcoming Earnings Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026)BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
